September 6, 2005 (tfi.fr LCI) - New markets for Solvay's continuous
dopaminergic stimulation (CDS) treatment Since 1 September 2005
Solvay Pharmaceuticals has been marketing and selling the product
DUODOPA(R) for the treatment of advanced Parkinson's disease in 12
new European countries: Belgium, Denmark, Finland, France, Greece,
Ireland, Italy, the Netherlands, Portugal, Spain, Germany and
Austria. Solvay Pharmaceuticals was previously already marketing the
product in Sweden and Norway and is currently in the process of
introducing this product in the United Kingdom. DUODOPA(R) joined
Solvay's product portfolio following the acquisition of Neopharma AB,
a Swedish pharmaceutical company, earlier this year. Until 1
September 2005, the product was distributed by Orphan Europe, a
company specialized in Orphan Drugs with headquarters in Paris,
France.
As part of the agreement with Orphan Europe, a number of Orphan
Europe's specialist Parkinson nurses will continue their work within
Solvay Pharmaceuticals in order to secure professional support of the
specialized treatment.

"Orphan Europe has done important work in preparing the
commercialization of DUODOPA(R) in Europe. By adding our own
resources we are confident to achieve a strong launch of DUODOPA(R),"
says Luc van Eesbeek, Business Group Manager for DUODOPA(R) at Solvay
Pharmaceuticals.

DUODOPA(R) is a new and unique treatment based on continuous
dopaminergic stimulation by means of a formulation of the well-known
substances, levodopa and carbidopa, dispersed in a viscous gel. Using
a patient-operated portable pump, the drug is continuously delivered
via a tube directly into the upper small intestine, where it is
rapidly absorbed. This delivery system ensures a more even supply and
uptake compared with conventional combination of tablet treatment.

The intestinal administration of DUODOPA(R) results in improved
mobility for patients with advanced Parkinson's disease, which in
turn leads to a more normal life with better opportunities for social
interaction and increased quality of life. DUODOPA(R) is indicated
for the treatment of severe Parkinson's symptoms and can be used as a
monotherapy offering the patient a documented more effective and
predictive treatment.

SOLVAY is an international chemical and pharmaceutical group with
headquarters in Brussels. It employs some 30,000 people (prior to
acquiring Fournier Pharma) in 50 countries. In 2004 its consolidated
sales amounted to EUR 7.9 billion generated by its three activity
sectors: Chemicals, Plastics and Pharmaceuticals. Solvay is listed on
the Euronext 100 index of top European companies.